Patents by Inventor James J. Powers

James J. Powers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF
    Publication number: 20240308965
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.
    Type: Application
    Filed: October 24, 2023
    Publication date: September 19, 2024
    Inventors: Donglei LIU, Julien PAPILLON, Stefan PEUKERT, James J. POWERS
  • 1,3-substituted cyclobutyl derivatives and uses thereof
    Patent number: 11845730
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: December 19, 2023
    Inventors: Donglei Liu, Julien Papillon, Stefan Peukert, James J. Powers
  • 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF
    Publication number: 20220324811
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.
    Type: Application
    Filed: March 24, 2022
    Publication date: October 13, 2022
    Inventors: Donglei LIU, Julien PAPILLON, Stefan PEUKERT, James J. POWERS
  • Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
    Patent number: 10550102
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: February 4, 2020
    Assignee: NOVARTIS AG
    Inventors: Christopher M. Adams, Doug Bevan, Michael Paul Capparelli, Takeru Ehara, Luciana Ferrara, Nan Ji, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna, Nello Mainolfi, Mitsunori Kato
  • INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20190119254
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 25, 2019
    Inventors: Christopher M. ADAMS, Doug BEVAN, Michael Paul CAPPARELLI, Takeru EHARA, Luciana FERRARA, Nan Ji, Erik MEREDITH, Muneto MOGI, James J. POWERS, Ganesh PRASANNA, Nello MAINOLFI, Mitsunori KATO
  • Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
    Patent number: 10208018
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 19, 2019
    Assignee: NOVARTIS AG
    Inventors: Christopher M. Adams, Doug Bevan, Michael Paul Capparelli, Takeru Ehara, Luciana Ferrara, Nan Ji, Mitsunori Kato, Nello Mainolfi, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna
  • Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
    Patent number: 9957254
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: May 1, 2018
    Assignee: Novartis AG
    Inventors: Christopher M. Adams, David B. Belanger, Doug Bevan, Philippe Bolduc, Takeru Ehara, Luciana Ferrara, Nan Ji, Mitsunori Kato, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna
  • CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20170197941
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 13, 2017
    Applicant: NOVARTIS AG
    Inventors: Christopher M. ADAMS, David B. BELANGER, Doug BEVAN, Philippe BOLDUC, Takeru EHARA, Luciana FERRARA, Nan JI, Mitsunori KATO, Erik MEREDITH, Muneto MOGI, James J. POWERS, Ganesh PRASANNA
  • INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20170197940
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 13, 2017
    Applicant: NOVARTIS AG
    Inventors: Christopher M. ADAMS, Doug BEVAN, Michael Paul CAPPARELLI, Takeru EHARA, Luciana FERRARA, Nan JI, Mitsunori KATO, Nello MAINOLFI, Erik MEREDITH, Muneto MOGI, James J. POWERS, Ganesh PRASANNA
  • 2-BENZYL-BENZIMIDAZOLE COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF
    Publication number: 20160311779
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: October 29, 2014
    Publication date: October 27, 2016
    Applicant: NOVARTIS AG
    Inventors: Christopher ADAMS, Takeru EHARA, Keith JENDZA, Nan JI, Toshio KAWANAMI, Nello MAINOLFI, James J. POWERS, Michael SERRANO-WU, Chun ZHANG, Rajeshri Ganesh KARKI
  • Complement factor B inhibitors and uses there of
    Patent number: 9475806
    Abstract: The present invention provides a compound of formula (I): wherein X is N or CH, Y is NH, O or S, methods for manufacturing these compounds, and their uses as Factor B inhibitors for the treatment of conditions and diseases associated with complement alternative pathway activation such as age-related macular degeneration, diabetic retinopathy and related ophthalmic diseases. The present invention further provides pharmaceutical compositions and combinations of pharmacologically active agents.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 25, 2016
    Assignee: Novartis AG
    Inventors: Christopher Michael Adams, Charles Babu, Michael Paul Capparelli, Jian Ding, Takeru Ehara, Keith Jendza, Nan Ji, Rajeshri Ganesh Karki, Toshio Kawanami, Liang Xue, Nello Mainolfi, James J. Powers, Michael H. Serrano-Wu, Chun Zhang
  • Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof
    Publication number: 20160145247
    Abstract: The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 17, 2014
    Publication date: May 26, 2016
    Applicant: NOVARTIS AG
    Inventors: David B. BELANGER, Stefanie FLOHR, Christine Fang GELIN, Keith JENDZA, Nan JI, Donglei LIU, Edwige Lilliane Jeanne LORTHIOIS, Rakeshri Ganesh KARKI, Nello MAINOLFI, James J. POWERS, Stefan Andreas RANDL, Olivier ROGEL, Anna VULPETTI, Taeyoung YOON
  • Complement Factor B inhibitors and uses there of
    Publication number: 20160024079
    Abstract: The present invention provides a compound of formula (I): wherein X is N or CH, Y is NH, O or S, methods for manufacturing these compounds, and their uses as Factor B inhibitors for the treatment of conditions and diseases associated with complement alternative pathway activation such as age-related macular degeneration, diabetic retinopathy and related ophthalmic diseases. The present invention further provides pharmaceutical compositions and combinations of pharmacologically active agents.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Applicant: NOVARTIS AG
    Inventors: Christopher Michael ADAMS, Charles BABU, Michael Paul CAPPARELLI, Jian DING, Takeru EHARA, Keith JENDZA, Nan JI, Rajeshri Ganesh KARKI, Toshio KAWANAMI, Liang XUE, Nello MAINOLFI, James J. POWERS, Michael H. SERRANO-WU, Chun ZHANG
  • SUPERCHARGED PULSE JET ENGINE AND RELATED METHOD OF USE
    Publication number: 20150275822
    Abstract: A system including a supercharged pulse jet engine is disclosed for the separation of a processing fluid. The system may include a rotary valve for introducing pockets of compressed air into the combustion chamber of the engine. Conditions of combustion may be adjusted in order to create “squared waves” within the exhaust to aid in separation. The processing fluid may be introduced into the exhaust stream of the engine, which may vaporize the process fluid, allowing compounds dissolved or suspended to be separated therefrom. The system may include a heat recovery system for pretreating the process fluid to conserve energy. Additionally, one or more separation elements such as an auger, a conveyor, a dust collector, a cyclone, or the like may be used to collect compounds separated from the process fluid. A condenser may be used to collect the fluid portion of the process fluid after separation.
    Type: Application
    Filed: March 23, 2015
    Publication date: October 1, 2015
    Inventors: James Clinton Furness, JR., David Adam Brentzel, Paul David Paulsen, James J. Powers, IV
  • Complement pathway modulators and uses thereof
    Publication number: 20150250767
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 19, 2015
    Publication date: September 10, 2015
    Applicant: NOVARTIS AG
    Inventors: Christopher Michael ADAMS, Charles BABU, Michael Paul CAPPARELLI, Jian DING, Takeru EHARA, Keith JENDZA, Nan JI, Rajeshri Ganesh KARKI, Toshio KAWANAMI, Liang XUE, Nello MAINOLFI, James J. POWERS, Michael H. SERRANO-WU, Chun ZHANG
  • Complement pathway modulators and uses thereof
    Patent number: 9056874
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 16, 2015
    Assignee: NOVARTIS AG
    Inventors: Christopher Michael Adams, Charles Babu, Michael Paul Capparelli, Jian Ding, Takeru Ehara, Keith Jendza, Nan Ji, Rajeshri Ganesh Karki, Toshio Kawanami, Liang Xue, Nello Mainolfi, James J. Powers, Michael H. Serrano-Wu, Chun Zhang
  • Complement pathway modulators and uses thereof
    Publication number: 20130296377
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 7, 2013
    Inventors: Christopher Michael ADAMS, Charles BABU, Michael Paul CAPPARELLI, Jian DING, Takeru EHARA, Keith JENDZA, Nan JI, Rajeshri Ganesh KARKI, Toshio KAWANAMI, Xue LIANG, Nello MAINOLFI, James J. POWERS, Michael H. SERRANO-WU, Chun ZHANG
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8541432
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: September 24, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8501756
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: August 6, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8492393
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: July 23, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao